Top Page
Xbrane Biopharma AB
(XBRANE)
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Xbrane Biopharma AB Business Overview & Revenue Model
Xbrane Biopharma AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 209.16M | 198.70M | 238.73M | 57.62M | 11.53M | 6.82M |
| Gross Profit | 146.28M | 180.47M | 35.39M | 41.04M | -684.00K | 2.45M |
| EBITDA | -23.81M | -181.97M | -282.03M | -149.34M | -167.59M | -213.07M |
| Net Income | 100.53M | -266.22M | -388.17M | -172.23M | -191.01M | -226.79M |
Balance Sheet | ||||||
| Total Assets | 701.48M | 842.43M | 653.51M | 690.51M | 688.43M | 463.76M |
| Cash, Cash Equivalents and Short-Term Investments | 93.56M | 124.33M | 65.40M | 193.99M | 295.18M | 243.14M |
| Total Debt | 0.00 | 191.72M | 231.48M | 38.22M | 44.38M | 6.26M |
| Total Liabilities | 114.43M | 633.89M | 482.17M | 265.63M | 256.69M | 206.06M |
| Stockholders Equity | 587.05M | 208.54M | 171.34M | 424.89M | 431.74M | 257.71M |
Cash Flow | ||||||
| Free Cash Flow | -179.47M | -185.97M | -423.45M | -254.04M | -296.96M | -242.26M |
| Operating Cash Flow | -89.22M | -133.73M | -406.68M | -193.92M | -219.61M | -238.41M |
| Investing Cash Flow | -59.21M | -52.25M | -16.77M | -60.13M | -77.35M | -3.85M |
| Financing Cash Flow | 214.93M | 243.62M | 298.70M | 148.86M | 349.37M | 322.72M |
Xbrane Biopharma AB Technical Analysis
Xbrane Biopharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | kr249.94M | 1.35 | -16.90% | ― | 4.64% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr396.46M | -3.64 | -79.60% | ― | ― | 31.62% | |
46 Neutral | kr346.23M | -2.83 | -16.51% | ― | ― | 31.37% | |
45 Neutral | kr310.14M | -2.41 | -25.66% | ― | 127.13% | 56.91% | |
42 Neutral | kr32.17M | -0.21 | -199.25% | ― | ― | 0.30% | |
41 Neutral | kr116.78M | -1.38 | -1291.15% | ― | ― | 28.54% |
Xbrane Biopharma AB Corporate Events
Xbrane Biopharma AB has issued 420,517 warrants to Fenja Capital II A/S as part of a conditional financing solution linked to a SEK 60 million loan agreement. This move follows a delay in the US FDA approval of Lucamzi, a proposed biosimilar for Lucentis. The issuance of warrants is a strategic step to address short-term financing needs and reflects market conditions after negotiations with Fenja Capital. The decision will result in a 2% dilution of shares if all warrants are exercised.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK8.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB announced plans to re-submit its Biologics License Application (BLA) for a ranibizumab biosimilar to the FDA in March 2026, following a Complete Response Letter due to issues at a contract manufacturer’s site. The company is addressing FDA’s corrective action requests and anticipates a six-month review process, aiming for approval by September 2026. This move is part of Xbrane’s commitment to offering a cost-effective treatment for conditions like Age-related Macular Degeneration, potentially strengthening its position in the biosimilar market.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK10.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB announced the inclusion of the first patient in the pivotal clinical trial for Xdivane, a nivolumab biosimilar candidate. This trial, sponsored by Intas Pharmaceuticals Ltd, is crucial for regulatory approval and aims to coincide with the Loss of Exclusivity of the reference product. The initiation of this trial has triggered a €2 million milestone payment to Xbrane, highlighting the potential market impact of Xdivane, which targets a growing market for immune-oncology drugs.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB has completed a reverse stock split at a ratio of 1:125, consolidating 125 existing shares into one new share, resulting in a total of 20,605,348 shares and votes as of October 31, 2025. This move is part of the company’s strategic financial restructuring, which may impact its stock liquidity and shareholder value, reflecting its ongoing efforts to strengthen its market position.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB announced that Siavash Bashiri, a member of its management team, has sold 14,733 shares to repay a loan taken during the 2024 rights issue. Despite the sale, Bashiri remains a committed long-term employee and shareholder, retaining 18,367 shares, which are his largest private financial investment. This move underscores his continued confidence in Xbrane’s future prospects.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma has addressed numerous stakeholder questions following a delay in FDA approval for its product Lucamzi, known as Ximluci in the U.S., and its Q3 report. The company has provided detailed responses to these inquiries, highlighting its commitment to transparency and stakeholder engagement amid regulatory challenges.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB reported a significant financial turnaround for the first nine months of 2025, with a profit of SEK 153.7 million compared to a loss the previous year, largely due to a strategic divestment to Alvotech. Despite challenges such as a delay in FDA approval for Ximluci® and a Complete Response Letter from the FDA, the company strengthened its financial position through a directed share issue and secured additional financing to support its operations. The initiation of a clinical trial for Xdivane™ marks a key step in its product pipeline, underscoring Xbrane’s commitment to advancing its biosimilar offerings.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK15.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB has announced a teleconference for investors, analysts, and media to discuss its interim report for January to September 2025, scheduled for October 24, 2025. The presentation, led by CEO Martin Åmark and CFO Jane Benyamin, will provide insights into the company’s performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB has announced the formation of its nomination committee for the upcoming 2026 Annual General Meeting. The committee, representing approximately 26% of the company’s shares and votes, includes members appointed by the company’s three largest shareholders. The committee’s responsibilities include preparing proposals for the Chairman of the Annual General Meeting, board candidates, and compensation matters, which will be presented ahead of the meeting. This development is significant for stakeholders as it outlines the governance structure and decision-making process leading up to the AGM, potentially impacting the company’s strategic direction.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB has received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for a ranibizumab biosimilar candidate, intended for treating retinal disorders. The CRL follows unresolved observations from a re-inspection of a contract manufacturer’s site, despite previous corrective actions. Xbrane plans to address these issues promptly to allow for re-submission. The company’s Lucentis biosimilar has been successfully approved and distributed in Europe, highlighting its commitment to providing cost-effective treatment alternatives.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK23.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma has entered into a conditional financing agreement with Fenja Capital II A/S to secure a SEK 60 million loan, which will be activated if there is a delay in the FDA approval of their Lucamzi biosimilar. While Xbrane remains optimistic about receiving FDA approval by the anticipated date, the financing solution is a proactive measure to ensure the company’s working capital needs are met in case of a delay. This move underscores Xbrane’s strategic planning to maintain financial stability and operational continuity, potentially affecting its market positioning and stakeholder confidence.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB announced a reverse share split at a 1:125 ratio, consolidating 125 existing shares into one new share. This move, effective from 17 October 2025, will change the ISIN code for Xbrane’s shares and adjust the total number of shares to 20,605,348. The reverse split aims to streamline the company’s share structure, with no action required from shareholders as the process will be handled automatically. Any excess shares will be sold by Eminova Fondkommission AB, with proceeds distributed to shareholders.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
Xbrane Biopharma AB held an extra general meeting where several key resolutions were passed, including amendments to the articles of association to adjust share limits and a reverse share split to consolidate shares. The meeting also approved a reduction in share capital to cover losses and allocate to unrestricted equity, and authorized the board to issue shares, warrants, and convertibles to raise new capital and increase flexibility. These decisions are aimed at strengthening the company’s financial position and expanding its shareholder base, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.